Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of RX518 as first-line treatment for EGFR-mutant advanced or metastatic non-small cell lung cancer
CTR20200563Phase 3Active
- Sponsor
- Suzhou Runxin Biotechnology
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olafertinib in non-small cell lung cancer (NSCLC), sponsored by Suzhou Runxin Biotechnology. Started Nov 2020; status: active.
02
Drugs
olafertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200563.